1. Signaling Pathways
  2. Anti-infection
  3. HIV

HIV

Human immunodeficiency virus

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1104A
    FC131 TFA
    Inhibitor 99.89%
    FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. Anti-HIV activity.
    FC131 TFA
  • HY-P1801A
    Cys-TAT(47-57) TFA
    98.04%
    Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.
    Cys-TAT(47-57) TFA
  • HY-P1065
    Apelin-36(rat, mouse)
    Inhibitor 99.12%
    Apelin-36(rat, mouse) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
    Apelin-36(rat, mouse)
  • HY-W587430
    Glycolithocholic acid 3-sulfate disodium
    Inhibitor 99.73%
    Glycolithocholic acid 3-sulfate disodium is a GPR39 agonist with EC50s of 47.9  and 66.8 μM (absence of Zn2+) and 8 and 8.7 μM (presence of Zn2+) in M39-20 and hGPR39-2 cells, respectively. Glycolithocholic acid 3-sulfate disodium stimulates GPR39 receptors to initiate intracellular calcium signaling, independent of Zn2+ binding sites H17 and H19. Glycolithocholic acid 3-sulfate disodium also inhibits replication of HIV-1 in vitro. Glycolithocholic acid 3-sulfate disodium can be used for the research of HIV infection and gallbladder disease.
    Glycolithocholic acid 3-sulfate disodium
  • HY-N3242
    Moronic acid
    Inhibitor 98.6%
    Moronic Acid is a triterpenoid compound, which is an orally available anti-HIV agent with anti-inflammatory activity. Moronic Acid can inhibit viral replication, with an EC50 value of <1 μg/mL. Moronic Acid can be isolated from Brazilian propolis.
    Moronic acid
  • HY-W251687
    2'-Deoxy-2'-fluoroarabinoadenosine
    Inhibitor 99.92%
    2'-Deoxy-2'-fluoroarabinoadenosine is a nucleoside analogue, which exhibits anticancer activity against human immunodeficiency virus (HIV).
    2'-Deoxy-2'-fluoroarabinoadenosine
  • HY-10224A
    Panobinostat lactate
    Activator 98.67%
    Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma.
    Panobinostat lactate
  • HY-B0689
    Indinavir
    Inhibitor 99.96%
    Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor.
    Indinavir
  • HY-18300A
    Filgotinib maleate
    Inhibitor 99.88%
    Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values ​​of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease.
    Filgotinib maleate
  • HY-P2260B
    Tat-beclin 1 scrambled
    99.01%
    Tat-beclin 1 scrambled is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus.
    Tat-beclin 1 scrambled
  • HY-B0957
    Erythromycin Ethylsuccinate
    Inhibitor ≥98.0%
    Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
    Erythromycin Ethylsuccinate
  • HY-137242
    Ingenol-3-palmitate
    Inhibitor 99.65%
    Ingenol-3-palmitate, an ingenane diterpenoid, is a nature product that could be isolated from the roots of Euphorbia ebracteolata. Ingenol-3-palmitate is a potent HIV-1 (HIV) inhibitor with an IC50 value of 4.1 nM.
    Ingenol-3-palmitate
  • HY-158128
    MK-8527
    Inhibitor 99.02%
    MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012).
    MK-8527
  • HY-145560
    Claficapavir
    Inhibitor 98.75%
    Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC50 around 1 μM. Claficapavir strongly binds the HIV-1 NC (Kd=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1.
    Claficapavir
  • HY-W074930
    (S)-Tenofovir
    Inhibitor 98.34%
    (S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
    (S)-Tenofovir
  • HY-107902
    RIG-1 modulator 1
    Inhibitor 99.54%
    RIG-1 modulator 1 (Compound of claim 13) is an anti-viral compound which can be used against viral infections including influenza virus, HBV, HCV and HIV.
    RIG-1 modulator 1
  • HY-134851
    HIV-1 inhibitor-6
    Inhibitor 99.10%
    HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50s ranging from 0.9 to 1.5 μM.
    HIV-1 inhibitor-6
  • HY-P10056
    HEP-1
    Inhibitor 98.01%
    HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases.
    HEP-1
  • HY-130000
    Pirmitegravir
    Inhibitor 99.76%
    Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties.
    Pirmitegravir
  • HY-106755
    Tucaresol
    Inhibitor 98.95%
    Tucaresol is an orally bioavailable immunopotentiatory drug that show to enhance T-helper-cell activity, with the induction of increased IL-2 and IFN-γ levels in mice and humans. Tucaresol has anti-HIV effect.
    Tucaresol
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.